Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P50
Within normal range
vs 2Y Ago
0.6x
Contraction
Streak
2 yr
Consecutive declineStable
| Period | Value |
|---|---|
| 2025 | 35.00% |
| 2024 | 38.26% |
| 2023 | 63.39% |
| 2022 | -24.45% |
| 2021 | 0.00% |